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ABSTRACT
Mutations in FUS cause amyotrophic lateral sclero-
sis (ALS), but the molecular pathways leading to
neurodegeneration remain obscure. We previously
found that U1 snRNP is the most abundant FUS in-
teractor. Here, we report that components of the U1
snRNP core particle (Sm proteins and U1 snRNA), but
not the mature U1 snRNP-specific proteins (U1-70K,
U1A and U1C), co-mislocalize with FUS to the cyto-
plasm in ALS patient fibroblasts harboring mutations
in the FUS nuclear localization signal (NLS). Similar
results were obtained in HeLa cells expressing the
ALS-causing FUS R495X NLS mutation, and mislo-
calization of Sm proteins is RRM-dependent. More-
over, as observed with FUS, knockdown of any of the
U1 snRNP-specific proteins results in a dramatic loss
of SMN-containing Gems. Significantly, knockdown
of U1 snRNP in zebrafish results in motor axon trun-
cations, a phenotype also observed with FUS, SMN
and TDP-43 knockdowns. Our observations linking
U1 snRNP to ALS patient cells with FUS mutations,
SMN-containing Gems, and motor neurons indicate
that U1 snRNP is a component of a molecular path-
way associated with motor neuron disease. Linking
an essential canonical splicing factor (U1 snRNP)
to this pathway provides strong new evidence that
splicing defects may be involved in pathogenesis and
that this pathway is a potential therapeutic target.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal motor neu-
ron disease with no available treatment, and disease mech-
anisms are not understood (1,2). Although ∼90% of ALS
cases are sporadic, mutations in numerous genes have been
identified that cause familial ALS, and studies of these genes
are leading to critical new insights into both forms of the
disease (1–3). Several ALS-causing genes encode nuclear
RNA/DNA binding proteins (4–7). These proteins are ex-
emplified by FUS and TDP-43, and recently, Matrin3 and
hnRNPA1 were added to the list (8–14). These proteins lo-
calize in the nucleus at steady state and have roles in RNA
processing and other steps of gene expression (4–7,11).
The relevance of RNA/DNA-binding proteins to ALS
is underscored by the observation that several other mo-
tor neuron diseases are caused by defects in these types of
proteins. A well-known example is the childhood disease
spinal muscular atrophy (SMA), which results from defi-
ciency of the SMN protein (15), a component of the SMN
complex. This complex localizes both diffusely in the cyto-
plasm and in nuclear Gems and is required for biogenesis
of the spliceosomal snRNPs (16). We previously found that
the ALS-causative protein FUS associates with the SMA-
causative protein SMN, and both FUS and SMN are each
required forGem formation (17,18). TDP-43 also associates
with both FUS and SMN and is required for Gem for-
mation (19). Thus, these two motor neuron diseases are
converging on the same molecular pathway, indicating its
potential significance in pathogenesis. The ALS-causative
proteins Matrin3 and hnRNPA1 interact with each other
and also with TDP-43 (11,20), suggesting that they are
also linked to this common pathway. Despite these asso-
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ciations among RNA/DNA binding proteins, it is not yet
known how defects in these proteins or this pathway cause
motor neuron disease. It is known that RNA/DNA bind-
ing proteins, such as TDP-43, FUS, and hnRNPA1, self-
associate via low-complexity domains present in these pro-
teins (5,7,21). This self-association is proposed to have a
normal role in the cell, which is to trigger assembly of cel-
lular bodies that concentrate factors with functions in the
same pathway, thereby increasing the efficiency and fidelity
of complex cellular pathways. Examples of such bodies in-
clude the nucleolus, Gems, nuclear speckle domains, and
P-bodies (5,7,21). Pathogenesis may arise when these self
assembly-prone proteins are mutated or altered in some
manner and instead form cytoplasmic aggregates (5,7,22–
23). The best-known example is observed with TDP-43, in
which cytoplasmic aggregates are found in neuronal cells in
the majority of ALS cases (24,25). FUS and hnRNPA1 ag-
gregates have also been observed in some cases (5,10,21,26).
It is not yet known whether the aggregates are pathogenic
due to decreased function of these proteins in the nucleus
and/or whether the aggregates themselves are toxic. A ma-
jor challenge in the field is to sort these issues out and clearly
define the pathways that are disrupted in motor neuron dis-
ease.
In light of our previous observations that FUS interacts
directly with SMN and that both proteins function in the
Gem pathway (17), we have now investigated the role of U1
snRNP in this pathway. Our interest inU1 snRNP stemmed
from our observation that it is the most abundant factor
that interacts with FUS in multiple assays in both HeLa
and neuronal cells (17,27). These links between FUS and
U1 snRNP, the SMN complex, andGems were also corrob-
orated in a new study in HeLa cells (28). In addition, as ob-
served with FUS, the SMN complex is known to associate
with U1 snRNP (29). However, the relationships between
FUS, the SMN complex, and U1 snRNP, as well as the po-
tential role of U1 snRNP in ALS are not yet understood. In
this study, we carried out a series of assays to address these
questions. We show that, as observed with FUS, the com-
ponents of U1 snRNP are essential for Gem formation in
HeLa cells.Moreover, ALS patient fibroblasts orHeLa cells
bearing FUSmutations in theNLS show co-mislocalization
of FUSwith Sm core proteins to the cytoplasm. U1 snRNA
is also mislocalized to the cytoplasm in these cells. To de-
termine whether U1 snRNP has a cell-type specific role in
motor neurons we knocked it down in zebrafish. This analy-
sis revealed a striking truncation of motor axons. Together,
our data link U1 snRNP to Gems, ALS patient cells with
FUS mutations, and motor axons, raise the possibility that
U1 snRNP is part of the pathway defective in motor neuron
disease. The sequestration of Sm proteins and U1 snRNA
by mutant FUS in ALS patient cells may also contribute to
the toxicity of FUS bearing NLS mutations.
MATERIALS AND METHODS
Cell lines
HeLa cells and fibroblasts were cultured using standard
conditions. Stable FUS and scrambled knockdown lines
were reported (17). FUS R521C fibroblasts were from a 40-
year-old female and FUS R514G were from a 39-year-old
male. The control was from a 40-year-old female. The pas-
sage numbers for all experiments were between 15 and 18.
Plasmids
FLAG-tagged wild type FUS, FUS R495X, FUS
R495X+RRM mut (changes in RRM: F305L, F341L,
F359L and F368L) (30) and FUS 174-R495X were con-
structed by inserting fragments into the BamHI and XhoI
sites of the vector pcDNA5/FRT/TO/i/FLAG, which
contains the Ftz intron and 3x FLAG tags in the AflII
and HindIII sites of pcDNA5/FRT/TO (Invitrogen),
respectively.
Antibodies
Antibodies to Gemin8 (IF8) and Sm (Y12) were from Ab-
cam. SMN (Mansma1) was from the Developmental Stud-
ies Hybridoma Bank. Coilin (F-7), FLAG, Gemin3 (C-5),
Gemin4 (E-8), Gemin5 (10G11), Gemin6 (20H8), Lamin
A/C, Snurportin (B-12), U1A (BJ-7) and U1C (5C9) were
from Santa Cruz. TMG (K121) and U1-70K (9C4.1) from
Millipore. Tubulin (DM1A) and SFRS2 were from Sigma.
The FUS antibody was described (17).
Immunofluorescence (IF)
IF was carried out using antibodies against FUS (1:2000),
SMN (1:400), U1-70K (1:2000), U1A (1:1000), U1C
(1:1000), U2B” (1:400), FLAG (1:1000), Y12 (1:1000),
Coilin (1:1000) and SRSF2 (1:1000). HeLa cells were fixed
with 4% paraformaldehyde in phosphate buffered saline
(PBS) for 15 min. Cells were permeabilized with 0.1% Tri-
ton X-100 in PBS for 15 min. For IF, cells were incubated in
the primary antibody overnight at 4◦C. After three washes
in PBS, the secondary antibody was added for 1 h at room
temperature, followed by three washes in PBS. Primary an-
tibodies were diluted in 10% calf serum in PBS. The sec-
ondary antibodies were mouse Alexa-488 and rabbit Alexa-
647 diluted 1:1000 in 10% calf serum in PBS. Images were
captured with a Nikon TE2000U inverted microscope, with
a PerkinElmer ultraview spinning disk confocal, and a 20×
objective using Metamorph software (Molecular Devices,
Sunnyvale, CA, USA).
Fluorescence in situ hybridization (FISH)
FISH for U1 snRNA was performed using a biotin-labeled
LNA probe (5′-GGTATCTCCCCTGCCAGGTAAGTAT-
3′) (31), obtained from Exiqon. Hybridization was per-
formed in 50% formamide, 2× SSC, 50 mM sodium phos-
phate (pH 7.0), and 10% dextran sulfate, containing 10 nM
LNA probe, at 37◦C overnight. After hybridization, cells
were washed in 2× SSC + 0.1% Triton X-100, followed by
detection with a fluorescent Alexa Fluor 594 streptavidin
conjugate. Cells were washed three times for 5 min each at
37◦C in 4× SSC + 0.1% Triton X-100, followed by washes
in 2× and 1× SSC, with a final wash in PBS at 25◦C.
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Quantitative RT-PCR
Total RNA was extracted with Trizol and treated with
DNase I for 15 min at 37◦C. DNase I stop solution was
added and the mixture was incubated at 65◦C to inacti-
vate DNase. After phenol extraction and ethanol precip-
itation, RNA was dissolved in H2O. One microgram of
RNA was used for each RT reaction. RNA was heated at
75◦C for 10 min in the presence of first strand transcription
buffer and gene specific primer (U1 snRNA Forward: 5′-
GATACCATGATCACGAAGGTGGTT-3′, Reverse: 5′-
CACAAATTATGCAGTCGAGTTTCC-3′, 5S RNA For-
ward: 5′-CGGCCATACCACCCTGAAC-3′, Reverse: 5′-
GCGGTCTCCCATCCAAGTAC-3′). The mixture was
then immediately chilled on ice for 5 min. deoxynucleotide
triphosphate (dNTP) mixture, dithiothreitol (DTT), and
RNase inhibitor were add and incubated at 37◦C for 2 min.
M-MLV RTase was then added and the RT reaction was
carried out. qPCR was performed using SYBRR© Green
PCR Master Mix (Invitrogen) using an ABI 7300 real-
time PCR system following the manufacturer’s instructions.
Data analysis was performed with SDS 2.3 software (Ap-
plied Biosystems). Values were normalized to Actin. Reac-
tions were carried out in triplicate and data were analyzed
using the comparative (C) method.
Microinjection of zebrafish embryos
The spawning of transgenic Tg(mnx1:GFP) zebrafish that
express GFP in ventrally projecting motor axons and the
care and husbandry of the embryos were carried out ac-
cording to standard protocols (32). The embryos were
injected at the one- to two-cell stage with the follow-
ing morpholino oligonucleotides (MO): U1-70K (5′-TGTT
CACCTCAGTTTTTCATTCGGC-3′), U1 AMO (5′-GG
TATCTCCCCTGCCAGGTAAGTAT-3′) (31), and stan-
dard control MO (5′-CCTCTTACCTCAGTTACAATTT
ATA-3′) (GeneTools Eugene, OR, USA). For the rescue
of U1-70K MO injection, the mutated U1-70K open read-
ing frame (to abolish the MO binding site) was amplified
with forward primer 5′- GAATTCGGATCCATGACG
CAATTCTTGCCGCCGAACCTGTTGG-3′ and reverse
primer 5′-CTCGAGTCTAGATTAGTACTCATCACCC
TGGGC-3′ and sub-cloned into the pCS2+ vector using
BamHI and XbaI sites. Plasmid DNA was linearized with
NotI and capped RNA was generated using the mMES-
SAGE mMACHINE Sp6 kit (Ambion, Austin, TX, USA)
following the manufacturer’s protocol. For the rescue ex-
periment, 50 pg of synthesized U1-70K mRNA was co-
injected with 0.7 ng of U1-70K MO into one- to two-cell
stage Tg(mnx1:GFP) embryos.
Zebrafish motor axon truncation
To visualize motor axons in GFP transgenic animals,
Tg(mnx1:GFP) zebrafish were fixed with 4% paraformalde-
hyde in PBS overnight at 4◦C, washed with PBST for 10
min, three times and mounted on slides for observation us-
ing a Zeiss Radiance 2100 laser scanning system together
with Laser-Sharp and LSM imaging software (Carl Zeiss
MicroImaging, Inc.). Tenmotor axons from each side of the
embryo were scored (total of 20 per embryo) at 28 h post-
fertilization and used to classify the embryo as one trunca-
tion, two truncations, three truncations or no defect. Three
sets of injections of embryos spawned the same day from
different parents were performed per condition and 200 em-
bryos (4000 motor axons) scored in each experiment. Sta-
tistical analysis was carried out using Prism 6 (GraphPad)
software. The distribution of larval classifications was an-
alyzed by comparing median values of each group with a
two-tailed student’s t test. Data are represented asmean and
standard error of the mean (SEM) from independent exper-
iments andP values are indicated as follows: *P< 0.05; **P
< 0.01; ***P < 0.001.
RESULTS/DISCUSSION
U1 snRNP-specific proteins are essential for Gem formation
in HeLa cells
Previous studies revealed that FUS is required for the pres-
ence of Gems in HeLa cells, motor neurons, fibroblasts and
other cell types (17,18). As U1 snRNP is such an abundant
FUS interactor, we first asked whether knock down of U1
snRNP components affects Gem levels in HeLa cells, us-
ing FUS and scrambled knockdowns for controls. The FUS
and U1 snRNP-specific protein knockdowns were efficient
as revealed by Western analysis (Figure 1A), and no sig-
nificant differences were observed in the levels of factors
that associate withU1 snRNP, including Sm proteins, SMN
complex components, and snurportin (Figure 1B). Consis-
tent with previous work, IF staining revealed that Gems
are present in the control knockdown cells but lost in the
FUS knockdown cells (Figure 1C, panels i and ii). Signif-
icantly, near complete Gem loss was observed in the three
U1 snRNP protein-specific knockdown cells whereas con-
trol cells had normal Gem levels (Figure 1C, panels iii–vi).
These data indicate that U1-70K, U1A, and U1C are each
required for the presence of Gems in HeLa cells. Our data
support the recent report that U1-70K knockdown results
in Gem loss in HeLa cells (33). Knockdowns of U1A and
U1C were not examined in their study (33). In a number of
cell types, including HeLa, Gems are found in association
with Cajal bodies, which are thought to function in snRNP
biogenesis and/or recycling (29). Consistent with previous
work, the Cajal body marker coilin, co-localizes with SMN
in control knockdown cells (Supplementary Figure S1A).
However, in the FUS or U1 snRNP-specific knockdown
cells, coilin-stained foci are still detected whereas SMN
staining of these foci is lost (Supplementary Figure S1A).
These data indicate that FUS and each of the U1 snRNP-
specific proteins is required for the presence ofGems but not
Cajal bodies inHeLa cells.We also observed no apparent ef-
fect of FUS or U1 snRNP-specific protein knockdowns on
nuclear speckle domains, which contain snRNPs and other
splicing factors (Supplementary Figure S1B). The observa-
tion that U1 snRNP, as found for FUS, TDP-43, and SMN,
is required for normal Gem levels indicates that U1 snRNP
is another key component of a molecular pathway that may
be disrupted in motor neuron disease.
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Figure 1. U1 snRNP-specific proteins are required for Gem formation. (A and B) HeLa cells stably expressing shRNA against FUS or transfected with
siRNAs against U1-70K, U1A, or U1C were used to knock down these proteins. Scrambled shRNA or siRNA was used as a negative control. The
knockdowns were analyzed byWestern using the indicated antibodies. Tubulin was used as a loading control. (C) IF of the indicated knockdown cells with
SMN antibodies (green) was used to detect Gems. DAPI (blue) was used to mark the nucleus. The merged images are shown. Scale bar: 20 m.
SmB snRNP core proteins are mislocalized to the cytoplasm
in ALS patient fibroblasts bearing NLS mutations in FUS
FUS is known to be mislocalized to the cytoplasm in ALS
patient fibroblasts bearing mutations in the NLS, which is
located between amino acids 495–526 (34). Themislocaliza-
tion is only partial because the cells contain one normal and
one mutant copy of FUS. Consistent with previous studies,
confocal images of IF staining showed that FUS is prop-
erly localized to the nucleus in fibroblasts from unaffected
controls and from patients with Alzheimer’s disease (AD)
or Parkinson’s disease (PD) (Figure 2A and B, panels i, and
Supplementary Figure S2A, i–v). In contrast, FUS is mislo-
calized to the cytoplasm in ALS patient fibroblasts bearing
anR514G (Figure 2A, panel vi) orR521C (Figure 2B, panel
vi) mutation. Thismislocalization of FUS in theALS versus
control fibroblasts can also be seen in lower magnification
widefield microscopy images of cell fields (Supplementary
Figure S2B and C, panels i–ii).
U1 snRNP contains the Sm snRNP core proteins (B/B’,
D1, D2, D3, E, F, G), the U1 snRNP-specific proteins (U1-
70K, U1A and U1C) and U1 snRNA. In light of our previ-
ous observation that all of these components of U1 snRNP
abundantly associate with FUS (17), we next examined the
distribution of U1 snRNP components in the ALS patient
and control fibroblasts. IF staining of control cells revealed
that SmB/B’ (hereafter referred to in the text as SmB) as
well as U1-70K, U1A, and U1C localized in the nucleus
(Figure 2A and B, panels ii–v, Supplementary Figure S2A
panels vi–x, Figure S2B, and Figure S2C panel iii). A weak
signal for SmB was also detected in the cytoplasm of con-
trol cells. This low level of cytoplasmic SmB signal is ex-
pected because the early steps of snRNP biogenesis take
place in the cytoplasm, including loading of the Sm core
proteins onto the snRNA via the SMN complex (35). The
snRNP-specific proteins (U1-70K, U1A, U1C) are subse-
quently loaded onto the snRNA in the nucleus (36). In strik-
ing contrast to the control cells, in the ALS patient fibrob-
lasts bearingmutations in theFUSNLS, IF staining of SmB
was not only detected in the nucleus, but also was abun-
dantly detected in the cytoplasm (Figure 2A and B, panel
vii). The mislocalization of SmB in the ALS patient fibrob-
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Figure 2. FUS and SmB are mislocalized to the cytoplasm in ALS patient fibroblasts bearing FUS mutations in the NLS. (A and B) IF with antibodies
against FUS, SmB,U1-70K,U1A, andU1Cwas carried outwithALSpatient cells carryingmutations in FUSR514G (A) orR521C (B). Control fibroblasts
from an unaffected individual (#34) were used as a control (and see Supplementary Figure S2 for five additional control fibroblasts). Scale bar: 50 m. (C
and D) The indicated patient fibroblasts were co-stained with FUS and SmB antibodies. The merged images are shown. Scale bar: 50 m.
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lasts versus control can readily be seen in lower magnifica-
tion images of the ALS patient fibroblasts (Supplementary
Figures S2B and S2C). Mislocalization is not due to gen-
eral leakiness of the nuclei as evidenced by the observation
that the three U1 snRNP-specific proteins (U1-70K, U1A,
U1C) were properly localized to the nucleus in the ALS pa-
tient fibroblasts (Figure 2A and B, panels viii–x). Analysis
of the fibroblasts by Western revealed that the overall levels
of FUS and SmB were similar (Supplementary Figure S2).
In support of the IF data, the Westerns showed increased
levels of both FUS and SmB in the cytoplasm in the ALS
patient (R514G) versus control fibroblasts whereas the U1
snRNP-specific proteins were only detected in the nucleus
in both types of fibroblasts (Supplementary Figure S2D).
We did not observe an obvious decrease in the nuclear lev-
els of FUS and SmB in the patient cells versus control. This
may be because some of the ALS patient cells show com-
plete absence of FUS from the nucleus whereas other cells
in the population have higher levels of nuclear FUS. There-
fore, the net amount of nuclear FUS may not differ in the
total cell population.We note that the FUS patient cell lines
grow extremely poorly compared to the control, AD, and
PD lines used in this study. This poor growth was observed
with different aliquots of the cells, and FUS R521C grows
so poorly that we were unable to obtain sufficient quanti-
ties of cells for Westerns or other biochemical studies. To-
gether, our data indicate that FUS and SmB, but not the
U1 snRNP-specific proteins, are mislocalized to the cyto-
plasm in the ALS patient fibroblasts bearing mutations in
the FUS NLS. We attempted to analyze additional Sm core
proteins by both IF andWestern but were not able to obtain
antibodies that worked in these assays. However, it is well
known that the Sm core proteins associate tightly with one
another and co-IP in a stoichiometric complex (37). Thus,
although it remains to be shown directly, themislocalization
of SmB may serve as a proxy for mislocalization of the en-
tire Sm core. Our observation that SmB mislocalizes to the
cytoplasmwhenmutant FUSmislocalizes is consistent with
previous work in which transfected NSC-34 cells expressing
FUS with NLS mutations showed a similar mislocalization
of SmB (38).
SmB co-mislocalizes with FUS in the cytoplasm
Our previous biochemical data showed that SmB associates
with FUS in an RRM-dependent, but NLS-independent
manner (17). Thus, we sought to determine whether mis-
localization of SmB could be explained by its association
with cytoplasmic FUS in the ALS patient cells. As shown
in Figure 2C and D (panel ii), the extent of FUS mislocal-
ization varies betweenmostly nuclear tomostly cytoplasmic
in the ALS fibroblast populations. Significantly, co-staining
revealed that SmB and FUS are mislocalized to similar ex-
tents in each of the cells (Figure 2C and D, panels ii and iv).
These data support the conclusion that mislocalization of
SmB occurs because it is sequestered in the cytoplasm by
mislocalized mutant FUS. As FUS is known to form inter-
molecular interactions with itself (17,39), it is possible that
the differences in levels of SmB and FUS mislocalization
are due to mutant FUS sequestering variable levels of wild
type FUS, which, in turn, sequesters variable levels of SmB.
U1 snRNA mislocalizes to the cytoplasm in ALS patient fi-
broblasts with FUS NLS mutations
It is known thatU1 snRNAassociates with the Sm core pro-
teins in the cytoplasm during snRNP biogenesis. Accord-
ingly, we next investigated the localization of U1 snRNA in
the ALS patient fibroblasts using FISH. This analysis re-
vealed that U1 snRNA was mislocalized to the cytoplasm
in both the FUS R514G (Figure 3A, panel ii) and R521C
(Figure 3A, panel iv) patient fibroblasts whereasU1 snRNA
was only nuclear in the control fibroblasts (Figure 3A, pan-
els i and iii). However, we also observed that the overall
FISH signal for U1 snRNA was stronger in both of the
ALS patient cell lines compared to the control (Figure 3A).
This increased level of U1 snRNA was validated by qPCR,
which revealed ∼1.5 fold more U1 snRNA in the ALS ver-
sus control fibroblasts (Figure 3B). It is possible that this
upregulation occurs because the nuclear levels of Sm pro-
teins have decreased due to their mislocalization to the cy-
toplasmbymutant FUS.A similar upregulation of snRNAs
was observed previously in an analysis of sporadic ALS
patient neuronal cells containing TDP-43 aggregates (18).
Thus, upregulation may be a common feature that occurs
with mislocalized or lower levels of snRNP proteins and/or
their associated proteins. The observation the SmB and U1
snRNA are mislocalized to the cytoplasm (this study and
(38)) could explain the decreased levels of Gems observed
in ALS patient fibroblasts and in cells expressing FUS with
NLS mutations (17,28,38). It has also been reported that
mutant FUS forms nuclear aggregates in ALS patient fi-
broblasts, and the decreased Gem levels may also be due
to loss of function of this mutant nuclear FUS (34,40).
SmB co-mislocalizes with FUSR495X to the cytoplasm in an
RRM-dependent manner
To further investigate the cytoplasmic sequestration of SmB
by FUS containing NLS mutations, we expressed the FUS
mutant, R495X, in HeLa cells. This mutation truncates
the NLS, which causes a severe and early onset form of
ALS (34,41–42). In addition, FUS R495X is known to be
strongly mislocalized to the cytoplasm (34). When we ex-
pressed wild type FLAG-tagged FUS in HeLa cells, IF
staining with a FLAG antibody revealed that FUS was nu-
clear (Figure 4A, panel i). In contrast, FLAG-tagged FUS
R495Xwasmainly detected diffusely in the cytoplasm (Fig-
ure 4A, panel iv). Analysis of the localization of U1 snRNP
components revealed that in all of the cells in which FUS
R495X was detected diffusely in the cytoplasm, a low but
reproducible level of SmB was also diffuse in the cytoplasm
(Figure 4A, compare panels iv and v). In contrast, the U1-
snRNP specific proteins (U1-70K and U1A) were only de-
tected in the nucleus in both the wild type andR495X trans-
fected cells (Supplementary Figure S3A and S3B). We pre-
viously found that SmB associates with FUS in an RNA-
dependent manner and requires the FUS RRM (17). Ac-
cordingly, we next mutated the RRM in FUS R495X and
examined SmB localization. This analysis revealed that al-
though FUS was mislocalized, SmB remained nuclear (Fig-
ure 4A, panels vii and viii). We conclude that SmB is se-
questered in the cytoplasm by mutant FUS, and the RRM
is required for this sequestration. The observation that the
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Figure 3. U1 snRNA is mislocalized to the cytoplasm in ALS patient fibroblasts bearing NLS mutations in FUS. (A) FISH was carried out to detect U1
snRNA in ALS patient fibroblasts harboring FUS mutations (R514G or R521C) and in control fibroblasts. Scale bar: 50 M. (B) U1 snRNA and 5S
RNA levels in ALS patient and control fibroblasts were determined by RT-qPCR in three separate experiments that were conducted in triplicate. Values
are expressed as mean ± SD. *P < 0.01, two-tailed Student’s t test.
U1 snRNP-specific proteins are properly localized in the
nucleus indicates that detection of SmB in the cytoplasm
is not due to a general leakiness of the nuclei in cells con-
taining FUS R495X. A likely reason that the Sm proteins
and U1 snRNA are mislocalized by mutant FUS is because
they are present in the cytoplasm during the SMN complex-
dependent assembly of the U1 snRNP core particle. Thus,
mutant FUS in the cytoplasm has the opportunity to in-
teract with the Sm proteins and U1 snRNA and sequester
these factors in the cytoplasm. Consistent with this conclu-
sion, previous work showed that FUS specifically associates
with U1 snRNP core particles (43). In the case of the U1
snRNP-specific proteins (U1-70K,U1A andU1C), they are
known to be imported independently of theU1 snRNP core
particle (44). Moreover, the U1 snRNP-specific proteins are
known to first associate with the U1 snRNP core particle in
the nucleus during assembly of the mature U1 snRNP (44).
Together, these data may explain why mutant FUS causes
mislocalization of the Sm proteins and U1 snRNA while
the U1 snRNP-specific proteins are properly localized. We
note that the number of cells expressingmutant or wild type
FUSwas low in our system and it was therefore not possible
to carry out biochemical studies using these cells.
FUS and Sm proteins co-aggregate in stress granules inHeLa
cells expressing FUS R495X
During our analyses of the transfected HeLa cells, we ob-
served that FUS R495X, but not wild type FUS, formed
cytoplasmic aggregates in a subset (∼5%) of the cells (Fig-
ure 4B, panel i). Moreover, these aggregates co-localized
with the stress granule marker, HuR (Figure 4B, panel ii).
Strikingly, we found that SmB also co-aggregates with FUS
R495X (Figure 4C, panels i and ii) whereas the U1 snRNP-
specific proteinswere properly localized to the nucleus (Sup-
plementary Figure S3C, panels ii and vi). Moreover, SmB
does not aggregate with FUS R495X when the RRM is
mutated (Figure 4D, panel v). We conclude that SmB, but
not the U1 snRNP-specific proteins, co-aggregates with
FUS R495X in cytoplasmic stress granules in an RRM-
dependent manner. It is known that proteins such as FUS
and TDP-43 form cytoplasmic aggregates in neuronal cells
(21,24–25). Thus, our observation that FUS can form ag-
gregates when expressed in HeLa cells may be related to ag-
gregate formation in neuronal cells. In previous studies in
yeast and drosophila, the RNA binding domains of FUS
and TDP-43 were found to be essential for mislocalization
of the respective proteins to stress granules as well as for
their toxic effects (25,45–46,30). Together, these observa-
tions support the view that the RNA binding capability of
ALS causing proteins, such as FUS and TDP-43, plays a
role in their pathogenesis.
Role of the FUS prion-like domain in localization of SmB
The N-terminus of FUS contains a loosely structured,
prion-like domain that participates in FUS aggregation and
is thought to play a critical role in ALS pathogenesis (1,4–
5,7,21,47–49). To determine whether this N-terminal do-
main of FUS affects SmB localization, we constructed FUS
174-R495X, in which both the N-terminal region and the
NLS are truncated. This analysis revealed a dramatic dif-
fusemislocalization of both FUS and SmB to the cytoplasm
(Figure 4E, panels i and ii). In addition, SmB was observed
in co-aggregates with FUS 174-R495X in the cytoplasm,
accompanied by a depletion of SmB staining from the nu-
cleus (Figure 4E, panels iv and v). In contrast, to SmB,
U1-70K is detected in the nucleus of cells expressing FUS
174-R495X regardless of whether FUS is diffuselymislocal-
ized to the cytoplasm or present in cytoplasmic aggregates
(Supplementary Figure 3D, compare panels i–ii and iv–v).
It is known that FUS forms an intramolecular interaction
(39) between the N and C termini of the protein. Thus, it is
possible that the dramatic mislocalization of SmB is due to
exposure of the FUS RRM when the N-terminus is trun-
cated and cannot form this intramolecular interaction, as it
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Figure 4. SmB is mislocalized to the cytoplasm in an RRM-dependent
manner in HeLa cells expressing FUS bearing the ALS-causative R495X
NLS mutation. (A) HeLa cells were transfected with FLAG-tagged WT
FUS (panels i–iii), FUS R495X (panels iv–vi), or FUS R495X + RRM-
mut (panels vii–ix) followed by IF with FLAG or SmB antibodies. (B and
C) HeLa cells were transfected with FLAG-tagged FUS R495X, and IF
was carried out with antibodies against FLAG (B, C), HuR (B) or Sm (C).
(D) HeLa cells were transfected with FLAG-tagged FUSR495X (panels i–
iii), or FUS R495X + RRMmut (panels iv–vi) followed by IF with FLAG
or SmB antibodies. (E) HeLa cells were transfected with Flag-tagged FUS
174-495X and IF was carried out with FLAG or SmB antibodies. (A–E)
DAPI was used to detect the nucleus. Scale bar: 20 m.
may increase the levels of RRM-dependent SmB binding to
FUS.
Knockdown of U1 snRNP in zebrafish causes motor neuron
defects
Previously, morpholino oligonucleotides (MOs) were used
to decrease the levels of SMN during zebrafish develop-
ment, revealing that SMN functions in motor axon out-
growth and branching (26). Similar phenotypes were ob-
served when FUS or TDP-43 was knocked down in ze-
brafish (50,51). To investigate a role for U1 snRNP in mo-
tor neurons, we knocked down U1 snRNP in zebrafish by
injecting U1-70K MO into transgenic Tg(mnx1:GFP) em-
bryos at the one- to two-cell stage. When 1.4 ng ofMOs was
injected, 75% (n = 600) of embryos injected with the U1-
70KMO survived to 28 h post-fertilization (hpf) compared
to 94% (n = 600) injected with the control MO. Signifi-
cantly, truncations of motor axons were observed in the sur-
viving 28 hpf embryos (Supplementary Figure S4A, panel
ii). However, these embryos showed abnormal morphology,
such as shortened body axis and kinked tail (Supplementary
Figure S4B, panel iii). When only 0.7 ng U1-70K MO was
injected, no abnormal morphology was observed (Supple-
mentary Figure S4B, panel ii). However, we observed strik-
ing truncations of motor axons in these 28 hpf embryos
(Figure 5A, panel ii, arrows), which is quantitated in Fig-
ure 5B. Moreover, the motor axon defect was rescued when
U1-70K MO was co-injected with U1-70K mRNA (Fig-
ure 5B, panel iii), indicating that the axon defect is specifi-
cally caused by U1-70K knockdown.
As another approach for investigating the role of U1
snRNP in axons, we injected zebrafish embryos with an
antisense morpholino (U1 AMO) that base pairs to U1
snRNA and prevents its base pairing to 5′ splice sites (31).
Whenwe injected low levels (1.5 ng) of theU1AMOor con-
trol MO into transgenic Tg(mnx1:GFP) embryos, morpho-
logical abnormalities were not observed. Significantly, how-
ever, motor axon truncation was observed when 1.5 ng of
the AMO was injected, and no defects were observed when
the control MO was injected (Figure 5C, panels i and ii;
quantitated in Figure 5D). Together, these data indicate that
knockdown of U1 snRNP specifically causes motor neuron
defects in developing zebrafish.
In this study, we have reported that the essential canon-
ical splicing factor, U1 snRNP, which is also an abundant
FUS and SMN interactor, is not properly localized to the
nucleus in ALS patient fibroblasts, is necessary for Gem for-
mation, and plays a role in motor axon outgrowth in ze-
brafish. These observations indicate that there is a growing
list of proteins, cellular machineries, and RNP bodies that
function in the pre-mRNA splicing pathway and also have
a particularly important role in motor neurons. So far, this
list includes SMN and the SMN complex, FUS, TDP-43,
hnRNPA1, MATRIN3 and now U1 snRNP. Although all
of these factors have functions in processes other than splic-
ing, the addition ofU1 snRNP to the list increases the likeli-
hood that defective splicing may be one of the key processes
that is pathogenic in motor neuron disease. Consistent with
this view, ALS-causing mutations such as FUS R521C as
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Figure 5. Knock down of U1 snRNP causes motor neuron defects in zebrafish. (A) Representative lateral views of motor axons in 28 hpf Tg(mnx1:GFP)
zebrafish embryos injected with a negative control MO (0.7 ng, panel i), an MO targeting U1-70K (0.7 ng, panel ii) or a combination of U1-70KMO and
U1-70K mRNA (panel iii). Arrows indicate truncated axons. (B) Quantitation of data shown in (A). Embryos were classified based on the number (0, 1, 2
or 3) of motor axon truncations and the percentage of each group is shown. (C) Representative lateral views of motor axons from 28 hpf zebrafish embryos
that were injected with control MO (i) or U1 AMO (ii) are shown. Arrows indicate truncated axons. (D) Quantitation of data shown in (C). Embryos were
classified based on the number (0, 1 or 2) of motor axon truncations and the percentage of each group is shown. Data in all graphs are represented as mean
and standard error of the mean.
well as knockdown of FUS, TDP-43 and SMN all result in
splicing defects (52–54).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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